An oral cancer drug shows promise against aggressive brain tumors

A national clinical trial led by the Alliance for Clinical Trials in Oncology has found that abemaciclib, an oral cancer drug, may slow tumor growth in patients with aggressive meningiomas that have specific genetic mutations. This primary analysis of Alliance A071401 is published in Nature Medicine.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup